InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations

invIOs GmbH, a biotech firm from Vienna, has successfully raised €8.2 million in Series A funding. This capital injection will fuel advancements in their immuno-oncology pipeline, focusing on both preclinical and clinical milestones through 2025.

The funding round saw strong participation from existing shareholders and Ligand Pharmaceuticals, who recently acquired invIOs' former parent company, APEIRON. CEO Peter Llewellyn-Davies expressed gratitude for the support and committed to pushing forward with their planned programs.

Key developments include INV501, an oral small molecule, in collaboration with Dana-Farber Cancer Institute, with target validation expected by Q1 2025. Additionally, INV441, a cell therapy using tumor-infiltrating lymphocytes, is set to begin human trials for glioblastoma by mid-2025.